Partner Therapeutics, INC.
UEI J33MSDBJZMC6 · MA · SAM.gov record ↗
$89.3M
FY2025 obligations
7
Contract awards
Aug 14, 2023
First action
Jun 15, 2026
Latest action
Obligations by agency
- Department Of Health And Human Services$89.1M
- Department Of Veterans Affairs$163K
Obligations by NAICS
Monthly obligations
Oct 24
Nov 24
Feb 25
Mar 25
May 25
Aug 25
Sep 25
Dec 25
Mar 26
Apr 26
May 26
Jun 26
Contracts ending within 18 months (recompete watch)
- 75A50323F80027 ↗$89.1M
LEUKINE 250MCG VIL INJ (5PKG)
- Ends
- Mar 28, 2027
- Started
- Sep 25, 2023
- Agency
- Office Of Assistant Secretary For Preparedness And Response
- NAICS
- 325412
| PIID | Description | Agency | NAICS | Obligated | Start | End |
|---|---|---|---|---|---|---|
| 75A50323F80027 ↗ | LEUKINE 250MCG VIL INJ (5PKG) | Office Of Assistant Secretary For Preparedness And Response | 325412 | $89.1M | Sep 25, 2023 | Mar 28, 2027 |
Largest awards
- 75A50323F80027 ↗$89.1M
LEUKINE 250MCG VIL INJ (5PKG)
- Ends
- Mar 28, 2027
- Started
- Sep 25, 2023
- Agency
- Office Of Assistant Secretary For Preparedness And Response
- NAICS
- 325412
- 36C24626N0782 ↗$73K
EMERG. BIZENGRI MEDS FOR VETERAN
- Ends
- Jul 9, 2026
- Started
- Jun 15, 2026
- Agency
- Department Of Veterans Affairs
- NAICS
- 325412
- 36C24626N0690 ↗$54K
EMERGENCY BIZENGRI MEDS. FOR VETERAN
- Ends
- May 18, 2026
- Started
- May 4, 2026
- Agency
- Department Of Veterans Affairs
- NAICS
- 325412
- 36C24626N0637 ↗$36K
EMERGENCY BIZENGRI MEDS FOR VETERAN
- Ends
- Apr 23, 2026
- Started
- Apr 9, 2026
- Agency
- Department Of Veterans Affairs
- NAICS
- 325412
R&D FOR REPURPOSING FX06, A HOST-DIRECTED THERAPY, FOR TREATMENT OF SEVERE DISEASE IN PATIENTS WITH SUDAN VIRUS DISEASE (SVD) OR OTHER FILOVIRUSES AOI #22 REBOOT
- Ends
- Jan 29, 2026
- Started
- Sep 24, 2023
- Agency
- Office Of Assistant Secretary For Preparedness And Response
- NAICS
- 541714
PARTNER THERAPEUTICS: THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO CONFIRM LEUKINE SAFETY IN SEPSIS PATIENTS, INFORM OPTIMAL LEUKINE DOSING, EXPLORE LEUKINE EFFICACY, AS WELL AS ADVANCE DEVELOPMENT OF MONOCYTE HUMAN LEUKOCYTE ANTIGEN-DR (MHLA-DR) AS
- Ends
- Mar 30, 2028
- Started
- Sep 29, 2024
- Agency
- Office Of Assistant Secretary For Preparedness And Response
- NAICS
- 541715
2025 PUBLIC LAW PRICING UPDATES
- Ends
- —
- Started
- Aug 14, 2023
- Agency
- Department Of Veterans Affairs
- NAICS
- 325412
| PIID | Description | Agency | NAICS | Obligated | Start | End |
|---|---|---|---|---|---|---|
| 75A50323F80027 ↗ | LEUKINE 250MCG VIL INJ (5PKG) | Office Of Assistant Secretary For Preparedness And Response | 325412 | $89.1M | Sep 25, 2023 | Mar 28, 2027 |
| 36C24626N0782 ↗ | EMERG. BIZENGRI MEDS FOR VETERAN | Department Of Veterans Affairs | 325412 | $73K | Jun 15, 2026 | Jul 9, 2026 |
| 36C24626N0690 ↗ | EMERGENCY BIZENGRI MEDS. FOR VETERAN | Department Of Veterans Affairs | 325412 | $54K | May 4, 2026 | May 18, 2026 |
| 36C24626N0637 ↗ | EMERGENCY BIZENGRI MEDS FOR VETERAN | Department Of Veterans Affairs | 325412 | $36K | Apr 9, 2026 | Apr 23, 2026 |
| 75A50123C00064 ↗ | R&D FOR REPURPOSING FX06, A HOST-DIRECTED THERAPY, FOR TREATMENT OF SEVERE DISEASE IN PATIENTS WITH SUDAN VIRUS DISEASE (SVD) OR OTHER FILOVIRUSES AOI #22 REBOOT | Office Of Assistant Secretary For Preparedness And Response | 541714 | $0 | Sep 24, 2023 | Jan 29, 2026 |
| 75A50124C00061 ↗ | PARTNER THERAPEUTICS: THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO CONFIRM LEUKINE SAFETY IN SEPSIS PATIENTS, INFORM OPTIMAL LEUKINE DOSING, EXPLORE LEUKINE EFFICACY, AS WELL AS ADVANCE DEVELOPMENT OF MONOCYTE HUMAN LEUKOCYTE ANTIGEN-DR (MHLA-DR) AS | Office Of Assistant Secretary For Preparedness And Response | 541715 | $0 | Sep 29, 2024 | Mar 30, 2028 |
| 36F79723D0171 ↗ | 2025 PUBLIC LAW PRICING UPDATES | Department Of Veterans Affairs | 325412 | $0 | Aug 14, 2023 | — |